• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Ophthotech

edit

Ophthotech Corporation is a privately held, clinical-stage biotechnology company located in Princeton, NJ and New York, NY.

There experience and expertise with back of the eye diseases enables us to concentrate on developing and commercializing therapies for both dry and wet Age-Related Macular Degeneration (AMD) in an accelerated manner.

Milestones

edit

• 
  Ophthotech added Nicholas Galakatos as Director.
  Posted 12/18/09 at 11:26am
• 
  Ophthotech added Alex Bolte as Director.
  Posted 12/18/09 at 11:26am
• 
  Ophthotech added Thomas Dyrberg as Director.
  Posted 12/18/09 at 11:26am
• 
  Ophthotech added Henry Simon as Director.
  Posted 12/18/09 at 11:26am
• 
  Ophthotech added David Guyer as Director.
  Posted 12/18/09 at 11:26am
• 
  Ophthotech added Evelyn Harrison as COO.
  Posted 12/15/09 at 10:00pm
• 
  Ophthotech added Samir Patel as President & CEO.
  Posted 12/15/09 at 10:00pm
• 
  Ophthotech received $30M in Series B funding. (12/15/09)
  Posted 12/15/09 at 10:00pm via fiercebiotech.com

Videos

Screenshots

edit

Above: Home Page
Uploaded: 12/16/09

Sources

1. Ophthotech nabs $30M round to fund AMD trial (fiercebiotech.com) [edit]